Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Rhea-AI Summary

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its upcoming participation in The Citizens Life Sciences Conference.

The company's senior management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 2:30 p.m. ET. Investors and interested parties can access the live webcast through Terns Pharmaceuticals' investor relations website at http://ir.ternspharma.com.

The presentation will be archived on the company's website for a minimum of 30 days after the event, allowing stakeholders who cannot attend the live session to review the discussion at their convenience.

Positive

• Company has a diversified portfolio focusing on high-value therapeutic areas (oncology and obesity)
• Active investor relations engagement through conference participation indicates strong market communication

Negative

• Still in clinical-stage with no commercialized products
• Focused on small-molecule products which may face intense competition in oncology and obesity markets

FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET.

A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for at least 30 days following the event.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Kaytee Bock
investors@ternspharma.com

Media
Jenna Urban
CG Life
media@ternspharma.com

FAQ

When is Terns Pharmaceuticals (TERN) presenting at The Citizens Life Sciences Conference 2025?

Terns Pharmaceuticals (TERN) will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET.

How can I watch Terns Pharmaceuticals' (TERN) Citizens Life Sciences Conference presentation?

You can watch the live webcast of Terns Pharmaceuticals' presentation on their investor relations website at http://ir.ternspharma.com. A replay will be available for at least 30 days after the event.

What areas of medicine does Terns Pharmaceuticals (TERN) focus on?

Terns Pharmaceuticals focuses on developing small-molecule product candidates for serious diseases, specifically in the areas of oncology and obesity.

Will Terns Pharmaceuticals' (TERN) May 7 presentation be recorded?

Yes, the fireside chat presentation will be recorded and archived on Terns' website for at least 30 days following the May 7, 2025 event.

What type of company is Terns Pharmaceuticals (TERN)?

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company listed on Nasdaq under the symbol TERN, developing small-molecule treatments for serious diseases.